IL1B and Insulin resistance: The anti-cytokine immunotherapy of type 2 diabetes is a new treatment method in recent years, especially blocking IL-1β in the process of impaired insulin secretion and insulin resistance, and can be used as a potential therapeutic target to reverse the quality and function of β cells [44–46].